S-甲基-S-(4-异丙基苯基)亚磺酰亚胺 | 1085526-18-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: S-甲基-S-(4-异丙基苯基)亚磺酰亚胺
• 英文名称: S-(4-isopropylphenyl)-S-methyl-sulphoximine
• 英文别名: S-Methyl-S-(4-isopropylphenyl) sulfoximine；imino-methyl-oxo-(4-propan-2-ylphenyl)-λ6-sulfane
• CAS: 1085526-18-6
• 化学式: C₁₀H₁₅NOS
• 分子量: 197.301
• InChiKey: OAGORAXGJPPUIZ-UHFFFAOYSA-N

物化性质

• 沸点：
  274.2±33.0 °C(Predicted)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  49.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC INHIBITORS OF ENPP1<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES D'ENPP1
  申请人：VOLASTRA THERAPEUTICS INC

  公开号：WO2021257614A1

  公开（公告）日：2021-12-23

  The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to triazolopyrimidine and imidazolopyrimidine inhibitors of ENPP1 and methods of their use for treating disease mediated by ENPP1.

  本公开涉及抑制细胞外核苷酸焦磷酸酶/磷酸二酯酶1（ENPP1）的抑制剂，其组成物和使用该化合物和其组成物的方法。更具体地，本公开涉及三唑嘧啶和咪唑嘧啶抑制剂的ENPP1及其使用方法，用于治疗由ENPP1介导的疾病。
• NOVEL SULPHOXIMINE-SUBSTITUTED QUINOLINE AND QUINAZOLINE DERIVATIVES AS KINASE INHIBITORS
  申请人：EIS Knut

  公开号：US20090226377A1

  公开（公告）日：2009-09-10

  The present invention relates to a quinoline or quinazoline derivative having the general formula (A): in which R 3 , R 4 , W, Y and Q are indicated in the description and the claims, the use of the compounds of the general formula (A) for the treatment of various disorders, and the preparation of compounds of the general formula (A).

  本发明涉及一种具有通式（A）的喹啉或喹嗪衍生物，其中R3、R4、W、Y和Q在说明书和权利要求书中指示，通式（A）化合物用于治疗各种疾病，以及通式（A）化合物的制备。
• Tank-binding kinase inhibitor compounds
  申请人：Gilead Sciences, Inc.

  公开号：US10040781B2

  公开（公告）日：2018-08-07

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  公开了具有下式（I）的化合物及其使用和制备方法：
• DIACYLGLYCEROL KINASE MODULATING COMPOUNDS
  申请人：GILEAD SCIENCES, INC.

  公开号：US20220324866A1

  公开（公告）日：2022-10-13

  The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.
• US8003787B2
  申请人：——

  公开号：US8003787B2

  公开（公告）日：2011-08-23